These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17452318)

  • 1. Nicotinic acid receptor agonists differentially activate downstream effectors.
    Richman JG; Kanemitsu-Parks M; Gaidarov I; Cameron JS; Griffin P; Zheng H; Guerra NC; Cham L; Maciejewski-Lenoir D; Behan DP; Boatman D; Chen R; Skinner P; Ornelas P; Waters MG; Wright SD; Semple G; Connolly DT
    J Biol Chem; 2007 Jun; 282(25):18028-18036. PubMed ID: 17452318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Langerhans cells release prostaglandin D2 in response to nicotinic acid.
    Maciejewski-Lenoir D; Richman JG; Hakak Y; Gaidarov I; Behan DP; Connolly DT
    J Invest Dermatol; 2006 Dec; 126(12):2637-46. PubMed ID: 17008871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
    Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ
    J Clin Invest; 2009 May; 119(5):1312-21. PubMed ID: 19349687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
    Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
    Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
    Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
    Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.
    Kim HY; Jadhav VB; Jeong DY; Park WK; Song JH; Lee S; Cho H
    Arch Pharm Res; 2015 Jun; 38(6):1019-32. PubMed ID: 25599616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A.
    Li G; Deng X; Wu C; Zhou Q; Chen L; Shi Y; Huang H; Zhou N
    J Biol Chem; 2011 Sep; 286(36):31199-212. PubMed ID: 21768093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.
    Li Z; Blad CC; van der Sluis RJ; de Vries H; Van Berkel TJ; Ijzerman AP; Hoekstra M
    Br J Pharmacol; 2012 Oct; 167(4):818-25. PubMed ID: 22616721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
    Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S
    J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes.
    Liu C; Kuei C; Zhu J; Yu J; Zhang L; Shih A; Mirzadegan T; Shelton J; Sutton S; Connelly MA; Lee G; Carruthers N; Wu J; Lovenberg TW
    J Pharmacol Exp Ther; 2012 Jun; 341(3):794-801. PubMed ID: 22434674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressing cell systems are a competitive option to primary adipocytes when predicting in vivo potency of dual GPR81/GPR109A agonists.
    Almquist J; Hovdal D; Ahlström C; Fjellström O; Gennemark P; Sundqvist M
    Eur J Pharm Sci; 2018 Mar; 114():155-165. PubMed ID: 29180298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.
    Carballo-Jane E; Gerckens LS; Luell S; Parlapiano AS; Wolff M; Colletti SL; Tata JR; Taggart AK; Waters MG; Richman JG; McCann ME; Forrest MJ
    J Pharmacol Toxicol Methods; 2007; 56(3):308-16. PubMed ID: 17643322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressing human GPR109A leads to pronounced reduction in plasma triglyceride levels in BAC transgenic rats.
    Masuda Y; Kurikawa N; Nishizawa T
    Atherosclerosis; 2018 May; 272():182-192. PubMed ID: 29625294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing.
    Sakurai T; Davenport R; Stafford S; Grosse J; Ogawa K; Cameron J; Parton L; Sykes A; Mack S; Bousba S; Parmar A; Harrison D; Dickson L; Leveridge M; Matsui J; Barnes M
    Eur J Pharmacol; 2014 Mar; 727():1-7. PubMed ID: 24486398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
    Pike NB
    J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
    Shen HC; Ding FX; Deng Q; Wilsie LC; Krsmanovic ML; Taggart AK; Carballo-Jane E; Ren N; Cai TQ; Wu TJ; Wu KK; Cheng K; Chen Q; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2009 Apr; 52(8):2587-602. PubMed ID: 19309152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.